Supplementary Figure 14: H1437 xenografts can be targeted by TPNCs carrying siRNA against MAGOHB or IPO13.

a, Individual tumor volumes for the xenograft experiment shown in Fig. 4b (n = 6 tumors per condition). The solid line connects the mean tumor volume at each time point. b, Individual tumor volumes for the xenograft experiment shown in Fig. 4e (n = 10 tumors per condition). Solid line overlays show mean ± s.e.m. for each condition at each time point. c, Surface expression for p32 (receptor for LyP-1-containing nanocomplexes) in H1437 cells, as assessed by flow cytometry. Results are from single experiment. d, H1437 tumor xenograft experiment performed by intra-tumoral injection of LyP-1-containing nanocompexes carrying either siGFP or siMAGOHB cargo. Thin lines show tumor growth in individual mice (n = 10 tumors per group). Solid lines show mean ± s.e.m. for each condition. e, Representative staining for cleaved caspase-3 in an siGFP-treated mouse (top) and an siMAGOHB-treated mouse (bottom) using LyP-1-based tumor-penetrating nanocomplexes. Staining was performed on n = 6 tumors per group (randomly selected). f, Quantification of staining levels in six randomly selected tumors from each group. Data are presented as mean ± s.d.; P value by two-tailed, two-sample t test.